PTEN pseudogene (PTENP1) has a tumor suppressive role in multiple cancers.
stages. However, approximately 20-30% patients with esophageal squamous cell carcinoma (ESCC), the predominant histological subtype of esophageal carcinoma, present with nodal or metastatic involvement even in its early stage. 5 In addition, ESCC patients respond poorly to conventional therapies such as surgical resection, radiation treatment, and chemotherapy. 6 In spite of the progression in precision oncology, the molecular basis of the ESCC is still largely unknown, impeding further pathogenetic studies of the disease. Exploring the detailed molecular mechanism may help clarify the pathogenesis and find more effective biomarkers for early detection and prognostic analysis of ESCC.
In recent years, mounting evidences have pointed out that long non-coding RNAs (lncRNAs) play crucial roles in the risk and progression of diverse cancers. Multiple studies have indicated that a group of lncRNAs, which could regulate the expression of proteincoding genes at chromatin organization, transcriptional and posttranscriptional levels, are aberrantly expressed in ESCC. Some of those lncRNAs were indicated as promising diagnostic and prognostic indicators of ESCC, such as HOTAIR, POU3F3, and SPRY4-IT1. [7] [8] [9] However, to the best of our knowledge, how lncRNA PTENP1 functions in ESCC pathogenesis remains unknown.
LncRNA PTEN pseudogene (PTENP1), transcripted by a highly conserved processed PTEN pseudogene, is previously reported to be correlated with multiple cancers, such as clear-cell renal cell carcinoma (ccRCC), gastric carcinoma and melanoma. [10] [11] [12] PTENP1, especially its 3′untranslated regions (3′UTR), acts as a competing endogenous RNA (ceRNA) that protects PTEN transcripts from microRNA-mediated downregulation at post-transcriptional level in several cancers, such as colon carcinoma and prostate cancer. 13 In addition, similar to that HMGA1 pseudogene (HMGA1Ps) regulates the expression of HMGA2, IGF2, and H19, PTENP1 is also capable of upregulating lots of other targets with tumor suppressive activities by functioning as a miRNAs' decoy. 13, 14 Furthermore, Gao et al found that expression of PTENP1 in oral squamous cell carcinoma tissues was negatively associated with patients prognosis. 15 Circulating PTENP1 in sera contributed to maintaining surveillance and forecast prognosis for patients with ccRCC or gastric cancer. 16, 17 This series of evidences suggest that PTENP1 has a tumor suppressive role, which goes beyond the regulation of PTEN alone, and PTENP1 can predict prognosis of cancer patients.
Considering all above, we hypothesized that PTENP1 may also play a crucial role in ESCC progression and could be associated with clinical outcomes of ESCC patients. To address our hypothesis, we first evaluated its expression in ESCC patients by exploring the Gene Expression Omnibus (GEO) database. Then we explored its function in ESCC through overexpressing its 3′UTR in vitro and in vivo, and further validated its expression in clinical tissues.
| MATERIALS AND METHODS

| Cell culture
The human ESCC cell lines Eca109 and TE-1 were purchased from the Cell Bank Type Culture Collection of Chinese Academy of Science (Shanghai, China) where cell lines were characterized by short-tandemrepeat DNA fingerprinting, mycoplasma detection and cell vitality detection. Cells were cultured in Modified RPMI Medium (Hyclone, Logan, UT) supplemented with 10% fetal bovine serum (Sijiqing, China), penicillin, and streptomycin (Corning, Shanghai, China). The
HEK-293T cells and human normal esophageal epithelial cells Het-1A
were kindly provided by the Translational Medicine Center of the First Affiliated Hospital of Xi'an Jiaotong University and grown in Dulbecco's modified Eagle's medium/High glucose (Hyclone) containing 10% fetal bovine serum, penicillin and streptomycin. All cell lines were maintained at 37°C in a humidified atmosphere with 5% CO 2 and passaged for fewer than 6 months in our laboratory after resuscitation.
| Downstream molecular prediction
sRNA target Database (StarBase v2.0) 18, 19 (http://starbase.sysu.edu.cn/) was used to identify downstream moleculars of PTENP1. StarBase collects interaction networks of miRNA-ceRNA, miRNA-ncRNA and protein-RNA from large-scale CLIP-Seq data. 18 It also provides miR-Function and ceRNA-Function web tools to predict the function of ncRNAs (miRNAs, lncRNAs, pseduogenes) and protein-coding genes from the miRNA-mediated (ceRNA) regulatory networks. 19 StarBase was commonly used in studying lncRNA-miRNA-mRNA network. [20] [21] [22] The primers for PTENP1, PTEN, SOCS6, Smad4, FOXO1, Smad5, KLF4, RUNX3, and GAPDH were purchased from Sangon Biotech. The annealing temperature was approximately 55°C. The sequences of the primers and the sizes of all the PCR products were shown in Supplementary Table S1. 2.5 | Cell proliferation, soft agar, and colony formation assay was used as a loading internal control. After incubation with recommended secondary antibody coupled to peroxidase, signals were detected using chemiluminescence reagent (Millipore) and ChemiDoc System (Bio-Rad, Hercules, CA). Finally, scanned images were quantified using ImageJ software.
| Overexpression of PTENP1 in ESCC cells
| Western blotting
| 3′UTR luciferase assay
To investigate whether PTENP1 3′UTR could decoy miR-17-5p from binding to SOCS6 mRNA, the plasmid of PTENP1 3′UTR, SOCS6 3′UTR, and SOCS6 3′UTR-MT and miR-17-5p as well as its control were synthesized (Genomeditech, China). The sequences of con- Clinical information of each patient was carefully retrieved from the medical records by two co-authors independently.
| Patients and tumor samples
| Statistical analysis
All statistical analysis was performed using SPSS 19.0 software. All quantative results were presented as the mean ± standard deviation from at least three independent experiments, unless indicated otherwise. The differences between two groups were analyzed using Student's t-test. The Kaplan-Meier method was used to calculate survival, and significance was determined by log-rank test. Multivariate logistic regression was performed to identify the independent factors related to ESCC prognosis. The relationship between PTENP1 expression levels and clinical parameters was assessed with χ 2 test.
Correlations were analyzed by Pearson rank correlation. Tests with twosided P values <0.05 were considered to be statistically significant.
| PTENP1 expression was down-regulated in ESCC tumor tissues and ESCC cell lines
The PTENP1 was down-expressed in various tumor types, which was suggested to contribute to cancer development. To investigate the expression of PTENP1 in ESCC patients, we first investigated its expression by employing the GEO database. The expression profile of 17 pairs of ESCC tissues and corresponding adjacent normal tissues was downloaded from the GEO database (GSE20347). 23 After statistical analysis, we found that the expression of PTENP1 was significantly lower in 88.235% ESCC samples comparing to the corresponding adjacent normal ones (t = 4.415, P < 0.001, Supplementary Figure S1A ). Moreover, as shown in Figure 1A , the expression of PTENP1 and PTEN were reduced in both Eca109 and TE-1 cells. As expected, after transfection PTENP1 expression was significantly increased in both Eca109 and TE-1 cells, respectively ( Figure 1B ).
| Effects of PTENP1 on cell proliferation in vitro
Subsequently, we measured the effects of PTENP1 overexpression on cell proliferation. The CCK-8 assay showed that in comparison with the controls, overexpression of PTENP1 significantly decreased the vitality of both two cell lines ( Figure 1C) . Consistently, the overexpression of PTENP1 significantly suppressed the colony numbers of both Eca109 and TE-1 cells measured by soft agar and colony formation assay ( Figures 1D and 1E ).
| PTENP1 overexpression promotes the suppressor of cytokine signaling 6 (SOCS6) expression
Given that PTENP1 was the pseudogene of PTEN, we first detected the expression of PTEN in Eca109 and TE-1 cells after transfection with PTENP1 3′UTR. However, we observed the elevated expression of PTEN only in Eca109 cells, but not in TE-1 cells (Figures 2A and 2B ).
Pseudogenes can regulate the expression of many other genes in addition
to their cognate gene. Therefore, we investigated possible candidate targets of PTENP1 using starBase v2.0. We found several downstream moleculars, including SOCS6, RUNX3, Smad4, Smad5, FOXO1, and KLF4. 13, 14, 18, 19 The expression of these targets in Eca109 and TE-1 cells was evaluated by qRT-PCR. As shown in Figures 2A and 2B , overexpression of PTENP1 in Eca109 and TE-1 cells remarkably increased the expression of SOCS6, while the expression of FOXO1 was slightly elevated. Therefore, we selected SOCS6 for subsequent experiments.
| PTENP1 may act through the SOCS6-p-STAT3-HIF-1α signal pathway
Overexpression of SOCS6, a well-known negative regulator of cytokine receptor signaling, could reduce p-STAT3 and HIF-1α levels in hepatocellular cancer and breast cancer. 24, 25 We speculated that in 3.5 | PTENP1 3′UTR decoyed miR-17-5p from binding to SOCS6 PTENP1, especially its 3′UTR, was previously reported to be a competing endogenous RNA (ceRNA) of PTEN. 13, 26 By functioning as a miRNAs' decoy, pseudogenes like HMGA1 or PTENP1 were capable of upregulating multiple targets with tumor suppressive activities. 13, 14 Such effect of PTENP1 may protect SOCS6 transcripts from microRNA-mediated downregulation at post-transcriptional level. [27] [28] [29] To investigate the involved miRNAs, all shared miRNAs were first predicted by starBase v2.0, resulted in miR-17/17-5p/20ab/20b-5p/ 93/106ab/427/518a-3p/519d, miR-204/204b/211, miR-382, miR-494, miR-544/544ab/544-3p, and miR-590-3p.
Further literature review suggested miR-17 and miR-93 may involve in the development of ESCC. 30, 31 In 3′UTR luciferase assay, ectopic expression of miR-17-5p mimics significantly diminished the luciferase activity of the reporter containing the wild-type 3′UTR of SOCS6, while PTENP1 3′UTR decoyed miR-17-5p from binding to SOCS6 ( Figures 3A and 3B ).
| PTENP1 inhibited tumorigenesis of ESCC in vivo
To investigate the effects of PTENP1 overexpression on the growth capacity of ESCC cells in vivo, the ESCC Eca109 cells transfected with PTENP1 3′UTR were injected subcutaneously into male nude mice. As shown by Figures 4A and 4B , xenografts derived from transfected group were significantly smaller compared with those derived from control mice in the checked time points. Subsequent immunohistochemistry analysis revealed that compared to control group, there were significantly elevated expression of SOCS6 (P = 0.0266) and depressed expression of Ki67, p-STAT3 (P = 0.0492), and HIF-1α (P = 0.0003), consistent with the result in vitro ( Figures 4C and 4D ).
| Correlation between PTENP1 and SOCS6 expression in ESCC patients
We investigated the expression of SOCS6 in GEO database (GSE20347) and found that similar to PTENP1, SOCS6 expression was also significantly lower in ESCC samples (t = 3.972, P = 0.001, Supplementary Figure S1B ). However, there was no correlation between PTENP1 and SOCS6 expression (r = 0.240, P = 0.353, Supplementary Figure S1C ).
We also evaluated the expression of SOCS6 in an independent cohort of 93 ESCC patients with stages II or III. The results showed that the expression of PTENP1 was positively correlated with the expression of SOCS6 in both mRNA (r = 0.255, P = 0.014) and protein level (r = 0.351, P = 0.001) (Supplementary Figure S2 ). Further analysis also identified correlation of positive rates of the molecules in SOCS6p-STAT3-HIF-1α signal pathway in ESCC clinical samples (Supplementary Figure S3 ).
| Lower expression of PTENP1 was correlated with poor prognosis of ESCC patients
According to the mean value of PTENP1 expression in these tumor tissues, patients were divided into a high expression group (n = 44) and a low expression group (n = 49). We then examined the potential associations between PTENP1 expression level and the clinicopathological characteristics of ESCC patients. As demonstrated in Table 1 , patients with lower PTENP1 expression tended to get a poorer histological grade (P = 0.037), more advanced TNM stage (P = 0.015), deeper infiltration depth (P = 0.045) and lymph node metastasis (P = 0.013) in ESCC tissues. Furthermore, Kaplan-Meier survival analysis indicated that ESCC patients with lower PTENP1 expression levels had a poorer overall survival (OS) than those with higher PTENP1 expression levels (P = 0.009, Figure 5 ). Further multivariate analysis also showed that PTENP1 expression (Hazard ratio = 0.216, P = 0.044) and TNM stage (Hazard ratio = 6.520, P = 0.001) were independent factors that affected the OS of ESCC patients after radical esophagectomy.
| DISCUSSION
LncRNA PTENP1 was reported to have a tumor suppressive function and presented lower expression in several cancers such as gastric carcinoma, ccRCC, colon carcinoma, and prostate tumor. 10, 11, 13 However, the expression of PTENP1 and the involvement of PTENP1 We found that the expression of PTENP1 was significantly downregulated in ESCC tissues compared with the corresponding adjacent normal ones. Moreover, low expression levels of PTENP1 in ESCC patients were significantly associated with numerous clinicopathological characteristics, including TNM stage, tumor infiltration depth, histological grade, and lymph node metastasis. We also found that PTENP1 expression level was an independent risk factor for OS after esophagectomy. These results suggested that PTENP1 could be a candidate to indicate prognosis of ESCC.
PTENP1 is reported to be hyper-methylated in multiple cancers cells and cell lines. 10, [32] [33] [34] For example, Marsit CJ identified PTENP1, rather than PTEN, was more likely to be hypermethylated in squamous cell carcinoma. 34 The result was further validated in colorectal, breast and haematological cancer cell lines. 33 hyper-methylation. 10 Considering these facts, it is reasonable to infer the down-regulation of PTENP1 in ESCC may also due to the hypermethylation of its DNA.
Previous studies have provided evidence that PTENP1, especially the 3′UTR of PTENP1, exerts tumor suppressive function in multiple cancers. 10, 12, 13, 35 In the present study, we found that the overexpression of lentiviral-mediated PTENP1 3′UTR significantly inhibited the proliferation of Eca109 and TE-1 cells. It is known that PTENP1 expression could regulate the expression of PTEN. 11, 13, 15, 36 However, we only observed elevated expression of PTEN in Eca109 whereas no significant alteration was found in TE-1 cell line. This may be explained by the variation of the PTENP1 abundance and subcellular localization in different cell lines, which remains to be further validated. Intriguingly, it has been demonstrated that pseudogenes' regulation upon target gene expression is sometimes more than functioning through their cognate genes. For instance, pseudogene-HMGA1P7 can regulate the expression of H19 and IGF2 as well as its cognate gene-HMGA1. 14 In the present study, we found that overexpression of PTENP1 resulted in the upregulation of SOCS6 expression in both mRNA and protein levels. SOCS6 has previously been found downregulated in multiple human cancers. [37] [38] [39] [40] [41] [42] We found the expression of SOCS6 was positively correlated with the expression of PTENP1 both in cell lines and in clinical samples. A similar trend was seen in data from GEO database despite it failed to reach the significance threshold, probably owing to the smaller sample size. Association between suppressed tumorgenesis and SOCS6 expression was also supported by our results of experiments in vivo and in vitro.
Moreover, SOCS6 is an important regulator of survival signaling. 37, 43 In the present study, PTENP1 3′UTR overexpression significantly inhibited the proliferation of ESCC cells. Our subsequent western blotting analysis identified that up-regulated PTENP1 expression in ESCC cell lines resulted in elevated levels of SOCS6 protein and reduced levels of p-STAT3 and HIF-1α.
Further 3′UTR luciferase assay identified that PTENP1 could regulate the expression of SOCS6 by miR-17-5p in ESCC.
Together these evidences suggested that PTENP1 may also affect SOCS6-p-STAT3-HIF-1α signal pathway in the pathogenesis of ESCC. SOCS6-p-STAT3-HIF-1α was previously reported to involve in modulating multi-drug resistance of hepatocellular cancer cells and TAM resistance of breast cancer cells. 24, 25 In this case, PTENP1 may also be involved in regulating multi-drug resistance of ESCC.
In conclusion, our study has preliminarily clarified the role of PTENP1 in ESCC, presenting the promising clinical value of this molecule. PTENP1 correlates with tumor progression in ESCC patients. PTENP1 is also a promising candidate of prognostic indicator for ESCC patients. We hope our discoveries could provide basic evidence for subsequent molecular studies of ESCC.
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